Abstract:IntroductionSmall cell lung cancer (SCLC) transformation serves as a significant mechanism of resistance to tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. To address this clinical challenge, we conducted a retrospective analysis at Zhejiang University School of Medicine, the First Affiliated Hospital, focusing on patients with EGFR sensitizing mutations.MethodsA total of 1012 cases were included in this retrospective analysis. The cohort primarily consisted of patients with EGFR sensitizing mutations. Biopsy-confirmed small cell transformation was observed in seven patients, accounting for 0.7% of the cases. All patients in this subset were initially diagnosed with stage IV adenocarcinoma (ADC), with four cases classified as poorly differentiated and three as moderately to poorly differentiated ADC. EGFR exon 19 deletions were identified in five of these cases. Next-generation sequencing (NGS) was performed on seven cases, revealing mutations in the tumor protein p53 (TP53) gene in four cases and loss of the retinoblastoma1 (RB1) gene in three cases.ResultsThe median duration from the initial diagnosis to small cell transformation was 35.9 months (interquartile range: 12.1–84 months). Following small cell transformation during EGFR inhibition, all patients received etoposide/platinum-based treatment, leading to a median progression-free survival (PFS) of 4.7 months (interquartile range: 2.7–10.1 months). Notably, most patients in this series had poorly differentiated adenocarcinomas at the outset. TP53 mutations and RB1 loss were common genetic alterations observed in patients with small cell transformation in this cohort.DiscussionThe findings underscore the clinical significance of SCLC transformation as a resistance mechanism to EGFR TKIs in NSCLC with EGFR mutations. The observed genetic alterations, including TP53 mutations and RB1 loss, suggest potential associations with the transformation process and warrant further investigation. Understanding the genetic landscape and clinical outcomes in patients experiencing small cell transformation can contribute to improved strategies for managing resistance in EGFR-mutant NSCLC.

EGFR-Mutated Squamous Cell Lung Cancer and Its Association with Outcomes.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors …

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

EGFR with TKI-sensitive Mutations in Exon 19 is Highly Expressed and Frequently Detected in Chinese Patients with Lung Squamous Carcinoma.

Clinical and Molecular Profiling of EGFR-mutant Lung Adenocarcinomas Transformation to Small Cell Lung Cancer During TKI Treatment

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

EGFR Mutations Subset in Chinese Lung Squamous Cell Carcinoma Patients

Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports

167P: Efficacy of EGFR-TKIs for Lung Squamous Carcinomas Harboring EGFR Mutation: A Multicenter Study and Pooled Analysis of Published Reports

How Sensitive Are Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation? A Bicenter Research and Pooled Analysis of Published Reports.

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Chinese Patients with Squamous Cell Carcinoma of Lung Harboring EGFR Mutation.

Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study